FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab perioperatively extends survival in resectable locally advanced HNSCC with PD-L1 CPS ≥1 – first checkpoint inhibitor approval.